D. Medical Signs an Additional U.S. Distribution Agreement for Spring Universal Infusion Sets
07 6월 2012 - 9:00PM
D. Medical Industries Ltd. (Nasdaq:DMED) (TASE:DMED) ("D. Medical"
or the "Company"), announced today that its indirect subsidiary,
Spring Health Solutions Inc. ("Spring Health"), has signed a
non-exclusive agreement with an undisclosed party for the
distribution of its Spring™ Universal Infusion Sets in the United
States.
The agreement has an initial term of two years, and will
thereafter be automatically renewed for one-year periods, unless
terminated by the parties. In addition, each party may terminate
the agreement upon three months prior written notice to the other
party.
"The new distribution agreement, signed in the U.S., will allow
us to bring the Spring Universal novel technology to even more
people with diabetes across the U.S. It is also aligned with our
strategy of focusing on partnering with high quality value
creators," said Efri Argaman, D. Medical's Chief Executive
Officer.
About the Spring Universal Infusion Set
The Spring Universal Infusion Set is compatible with most
insulin pumps currently available on the market. Going beyond the
minimum requirements of subcutaneous drug delivery, the Spring
Universal offers best-in-class features such as a hidden,
auto-retractable needle, 360 degree connector, and smallest
one-click, all-in-one inserter.
The core of the Spring Universal Infusion Set is the proprietary
Detach-Detect mechanism. In the case, the base of the infusion set
detaches from the user's body, a blocking mechanism is triggered
which, in turn, creates an occlusion. This evokes an occlusion
alarm in an insulin pump. This unique feature enables exceptional
reliability for continuously controlled and monitored insulin
delivery, providing additional safety and peace of mind -
especially for athletes and the parents of pediatric patients.
About D. Medical
D. Medical is a medical device company that holds through its
subsidiaries a portfolio of products and intellectual property in
the area of insulin and drug delivery. D. Medical has developed
durable and semi-disposable insulin pumps, which continuously
infuse insulin into a patient's body, using its proprietary
spring-based delivery technology. D. Medical believes that its
spring-based delivery mechanism is cost-effective compared to the
motor and gear train mechanisms that drive competitive insulin
pumps and also allows it to incorporate certain advantageous
functions and design features in its insulin pumps. For more
information, please visit http://www.dmedicalindustries.com
(corporate) and http://www.springnow.com (healthcare professionals,
patients and care givers).
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by the Israeli Securities Law, 1968, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) that involve risks and
uncertainties. The forward-looking statements are based on D.
Medical's current expectations and beliefs which are based on,
among other things, its analysis of publicly available information
and market research reports. All forward-looking statements are
subject to certain risks, uncertainties and assumptions that could
cause actual results to differ materially from those described in
the forward-looking statements. Such risks and uncertainties
include, but are not limited to, the impact of general economic
conditions, competitive products, product demand, product
performance, the performance of D. Medical's contract manufacturer
and distributors, regulatory trends and approvals and healthcare
reform legislation. If one or more of these risks and/or
uncertainties materialize, or if the underlying assumptions prove
to be incorrect, D. Medical's actual results, performance or
achievements could differ materially from those expressed in, or
implied by, any such forward-looking statements or results which
are based upon such assumptions. No assurances can be given that
any of the events anticipated by the forward-looking statements
will transpire or occur, or if any of them transpire or occur, what
impact it will have on D. Medical's results of operations or
financial condition. D. Medical does not undertake to update any
forward-looking statements.
CONTACT: Company Contact:
Amir Loberman
Chief Financial Officer
D. Medical Industries LTD
T: +972-73-2507135
info@springnow.com
North American Investor Contact:
Stephen Kilmer
Kilmer Lucas Inc.
T: 212-618-6347
stephen@kilmerlucas.com
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024